Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
kensuke Egashira Last modified date:2019.04.08

Professor / Center for Cardiovascular Disruptive Innovation
Faculty of Pharmaceutical Sciences


Graduate School
Undergraduate School
Other Organization
Administration Post
Other


E-Mail
Homepage
[URL].
Academic Degree
Doctor of Medicine
Field of Specialization
Cardiovascular Medicine, Vacular biology and medicine, Frontier medicine, nano medicine
Outline Activities
Kensuke Egashira, MD, PhD is Associate Professor and the director of vascular biology and translational medicine unit in the Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine in Fukuoka, Japan. http://www.med.kyushu-u.ac.jp/cardiol/research_units/trans/index.html
He has received numerous awards and recognitions for his research accomplishments. His area of clinical expertise is in cardiovascular medicine.

His current major research focus is on the role of inflammation in atherosclerotic vascular diseases and on application of nanotechnology-based drug-delivery system (DDS) for the development of innovative therapeutic strategy and molecular imaging technology. As principal investigator, he leads several National Translational Research Programs of Nanomedicine, which comprises the development of nanoparticle-eluting stent, DDS catheters, therapeutic arteriogenesis for treatment of organ ischemia, imaging /stabilization of vulnerable atherosclerotic plaques for treatment of acute myocardial infarction, protection of organ ischemia-reperfusion injury, etc.

Dr. Egashira has published extensively in medical journals including Circulation, Journal of Clinical Investigation, New England Journal of Medicine, Lancet, etc (259 original papers, total impact factor = 2176.345, total citation index = 13,805 until 2013). Dr. Egashira has been selected to deliver numerous lectures in Japanese and International Societies. He is the recipient of a Sato Prize from Japanese Circulation Society and a Science and Technology Prize from the Ministry of Education, Culture, Sports, Science and Technology, Japan. Dr. Egashira holds more than 10 items of issued or filed international patents for promotion of his basic research findings to clinical medicine.

Dr. Egashira has a number of professional memberships for many medical societies including Japanese Circulation Society (Fellow), Japan Atherosclerosis Society (Fellow), Japanese Society of Vascular Biology and Medicine (Trustee), American Heart Association (Fellow), and European Society of Cardiology (Fellow). He serves as the editorial board member of Arterioscler Thromb Vasc Biol.
Research
Research Interests
  • Creation of Advanced Nanomedicine from Integration of the Unique Advanced Technologies (Medicine, Medical Engineering and Nanotechnology)
    keyword : atherosclerosis, restenosis, nanotechnology, DDS, less invasive medicine
    2004.01~2014.03.
  • Creation of Original Gene Therapy and Cell Therapy Based on Known Molecular Mechanisms of Arteriosclerotic Disease
    keyword : atherosclerosis, restenosis, inflammation, gene therapy, cell therapy
    2000.01~2014.03.
  • Molecular Mechanism of Ischemic Heart Diseases: Basic and Clinical Research on the Role of Vascular Endothelial Dysfunction
    keyword : ischemic heart disease, atherosclerosis, endothelial function
    1998.01~2014.03.
Current and Past Project
  • Gene therapy against restenosis and atherosclerosis.
  • Research development and clinical application of less invasive inherent therapy for treatment of severe pulmonary arterial hypertension
  • Translational research for development of new therapeutic angiogenesis/arteriogenesis with nanotechnology-based cell selective delivery into the vascular endothelium
  • Formulation of inteligent nanotechnology-based DDS and nanoparticle-eluting stent
Academic Activities
Books
1. Egashira K, Mohri M, Takeshita A,Endothelial Dysfunction in Cardiac Syndrome X (Microvascular Angina). In The Pathogenesis of Angina Pectoris and Normal Coronary Arteries.,Kluwer Academic Publishers.,91-100,1999.01.
Reports
1. Egashira K,Molecular Mechanisms Mediating Inflammation in Vascular disease -special Reference to Monocyte Chemoattractant Protein-1-,41: 834-841.,Hypertension 2003;,2003.01.
Papers
1. Egashira K, Tomoike H, Yamamoto Y, Yamada A, Hayashi Y, Nakamura M,Histamine-Induced Coronary Spasm in Regions of Intimal Thickening.,Circulation,Vol.74,No.4,74: 826-837,1986.01.
2. Egashira K, Inou T, Yamada A, Hirooka Y, Takeshita A,Preserved endothelium -dependent vasodilation at the vasospastic site in patients with variant angina.,J Clin Invest,Vol.89,No.3,89(3) :1047-1052,1992.01.
3. Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y, Takeshita A,Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine.,Circulation,Vol.88,No.1,88(1): 77-81,1993.01.
4. Egashira K,Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita,Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms.,N Engl J Med,Vol.328,No.23,328(23): 1659-1664,1993.01.
5. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A,Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions.,J Clin Invest,Vol.91,No.1,91(1):29-37,1993.01.
6. Egashira K, Katsuda Y, Mohri M, Kuga T, Tagawa T, Kubota T, Hirakawa Y, Takeshita A,Role of of endothelium-derived nitric oxide in coronary vasodilatation induced by pacing tachycardia in humans.,Circulation Research,Vol.79,No.2,79(2):331-335,1996.01.
7. Egashira K Hirooka Y Mohri M Kuga T Takeshita A,Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation induced by acetylcholine in patients with angina and normal coronary arteriograms.,Circulation,Vol.94,No.2,94(2):130-134,1996.01.
8. Egashira K, Katsuda Y, Mohri M, Kuga T, Tagawa T ,Shimokawa H ,Takeshita A,Basal release of endothelium-derived nitric oxide at the spastic site in patients with variant angina.,J Am Coll Cardiol,Vol.27,No.6,27(6):1444-1449,1996.01.
9. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A,Important role of tissue angiotensin-converting enzyme activit in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats.,J Clin Invest,Vol.99,No.2,99(2): 278-287,1997.01.
10. Mohri M, Koyanagi M, Egashira K, Tagawa H, Ichiki T, Tagawa T, Shimokawa H, Takeshita A,Angina pectoris caused by coronary microvascular spasm.,Lancet,Vol.351,No.9110,351:1165-1169,1998.01.
11. Kitamoto S, Egashira K, Kataoka C, Koyanagi M, Katoh M, Shimokawa H, Morishita R, Kaneda Y, Sueishi K, Takeshita A,Increased activity of nuclear factor kB participates to cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats.,Circulation,Vol.102,No.7,102(7): 806-812,2000.01.
12. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A,Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis in rats.,Circulation,Vol.102,No.18,2243-2248,2000.01.
13. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A,Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by blockade of nitric oxide synthesis.,Circulation,Vol.101,No.3,101(3): 305-310,2000.01.
14. Ni WH, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida K, Takeshita A,New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Inhibits Atherosclerosis in ApoE-knockout Mice.,Circulation,Vol.103,No.16,103(16): 2096-2101,2001.01.
15. Inoue S, Egashira K, Ni WH, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K Takeshita A,Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Limits Progression and Destabilization of Established Atherosclerosis in Apolipoprotein E-Knockout Mice.,Circulation,Vol.106,No.21,106:2700-2706,2002.01.
16. Ohtani K, Egashira K, Hiasa K, Zhao Q, Kitamoto S, Ishibashi M, Usui M, Inoue S, Yonemitsu Y, Sueishi K, Sata M, Shibuya M, Sunagawa K,Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. ,Circulation,Vol.110,No.16,110: 2444-2452,2004.01.
17. Hiasa K, Ishibashi M, Otani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A, Egashira K,Gene Transfer of Stromal Cell-Derived Factor-1α Enhances Ischemic Vasculogenesis and Angiogenesis via Vascular Endothelial Growth Factor / Endothelial Nitric Oxide Synthase-Related Pathway: Next-Generation Chemokine Therapy for Therapeutic Neovascularizaiton,Circulation,Vol.109,No.20,109(20): 2454-2461,2004.01.
18. Ohtani K,Egashira K,Nakano K, Zhao G, Funakoshi K, Ihara Y, Kimura S, Tominaga R, Morishita R, Sunagawa K,Stent-based local delivery of nuclear factor-kB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits.,Circulation,114(25): 2773-2779,2006.01.
19. Egashira K, Nakano K, Ohtani K, Funakoshi K, Zhao G, Ihara Y, Koga J, Kimura S, Tominaga R, Sunagawa K,Local Delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys.,Artemoscler Thromb Vasc Biol.,27(12): 2563-2568,2007.01.